Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

Table 1 Headache characteristics during baseline, the last 4 weeks of open-label extension (OLE) and the observation period of 12 weeks following OLE termination (pooled data)

	Baseline (before randomization)	Last 4 weeks of OLE	Week 1–4 after OLE completion	Week 5–8 after OLE completion	Week 9–12 after OLE completion
Monthly migraine days
	18.38 ± 3.74	12.19^a ± 4.53	13.00^a ± 6.61	13.81^a ± 5.96	14.20^a ± 6.88
p value vs. baseline		< 0.001	0.001	0.001	0.014
p value vs. last 4 weeks of OLE			0.539	0.154	0.299
Change in monthly migraine days (vs. baseline)
	n.a.	−6.19^a ± 3.43	−5.38^a ± 4.92	−4.75^a ± 4.15	−3.93 ^a ± 5.46
p value		< 0.001	0.001	0.001	0.014
Change in monthly migraine days (vs. last 4 weeks of OLE)
	n.a.	n.a.	+ 0.81 ± 5.17	+ 1.62 ± 4.33	+ 1.87 ± 6.70
p value			0.539	0.154	0.299
Headache hours
	140.56 ± 80.49	90.75^a ± 57.08	91.80^a ± 66.58	108.13 ± 69.90	113.60 ± 82.94
p value vs. baseline		0.004	0.017	0.067	0.147
p value vs. last 4 weeks of OLE			0.917	0.098	0.191
Days with severe headache
	5.38 ± 4.06	1.69^a ± 1.70	2.21^a ± 3.26	3.50 ± 4.45	3.86^a ± 3.37
p value vs. baseline		0.003	0.003	0.069	0.048
p value vs. last 4 weeks of OLE			0.683	0.165	0.039
Days with acute headache medication use
	12.75 ± 5.16	8.94^a ± 5.60	10.38^a ± 7.50	10.69 ± 7.28	10.67 ± 7.87
p value vs. baseline		0.001	0.032	0.085	0.118
p value vs. last 4 weeks of OLE			0.179	0.140	0.305
Days with triptan use
	10.25 ± 7.38	6.06^a ± 6.62	6.88^a ± 8.28	8.06 ± 8.52	8.00 ± 8.21
p value vs. baseline		0.001	0.013	0.115	0.126
p value vs. last 4 weeks of OLE			0.327	0.032	0.114

ISSN: 1129-2377